Currently Viewing:
COA Community Oncology Conference 2019
COA Close to Filing OCM 2.0 for Federal Review
April 05, 2019
Strategies for Fighting Consolidation in Community Oncology
April 05, 2019
Katie Goodman: Bring Clinical Trials to the Community Setting to Meet Patients Where They Are
April 05, 2019
Dr Howard Burris on Efforts Needed to Ensure Access to NGS Testing
April 05, 2019
Dr Lee Schwartzberg Explains the Promise of Liquid Biopsies in Cancer
April 06, 2019
Currently Reading
Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers
April 06, 2019
Step Therapy in Medicare Advantage Hurts Patients, Providers, Says Schwartzberg
April 06, 2019
Dr Basit Chaudhry Outlines Findings From OCM PP3
April 07, 2019
Dr Jeffrey Scott on Pharma's Role in Understanding the Value of Novel, Expensive Therapies
April 07, 2019
Dr Jeff Patton on OCM PP3 Results, Challenges With the Model
April 09, 2019
Dr Sonia T. Oskouei Discusses Uptake, Cost Savings With Filgrastim Biosimilar Xarzio
April 11, 2019
Katie Goodman on FDA's Efforts to Expand Patient Inclusion Criteria for Clinical Trials
April 11, 2019
Dr Lee Schwartzberg Reflects on the Approval of the First Immunotherapy Regimen in Breast Cancer
April 12, 2019
Dr C.K. Wang on How Real-World Data Provide a More Comprehensive Picture of Drug Efficacy
April 14, 2019
Dr Basit Chaudhry on Challenges With Improving Performance Under OCM
April 17, 2019
Dr Jeff Patton Explains How Physician Shortage, Burnout Are Impacting Community Oncologists
April 22, 2019
Dr Lee Schwartzberg on Genetic Testing for All Patients Diagnosed With Breast Cancer
April 23, 2019
Dr Sonia Oskouei Explains the Importance of Education Around Biosimilars
April 24, 2019
Katie Goodman Discusses Clinical Trial Participation Criteria's Impact on Trial Participation
April 25, 2019
Dr C.K. Wang: How COTA's Real-World Data Platform Helps Oncologists Make Informed Decisions
April 27, 2019
What Dr Howard Burris Will Focus on as ASCO President
April 28, 2019
Dr Basit Chaudhry: Evaluating the Adequacy of Novel Therapy Adjustment Under OCM
April 29, 2019
Dr Lee Schwartzberg Outlines Challenges With Accessing Multigene Testing in the Community Setting
May 07, 2019
Dr Jeff Patton Discusses CMS' Proposal to Ease Protections on 6 Drug Classes in Part D
May 08, 2019

Dr C.K. Wang Discusses How Real-World Data Can Benefit Payers

C.K. Wang, MD, senior medical director, COTA, explains how COTA's real-world data platform can benefit payers.


C.K. Wang, MD, senior medical director, COTA, explains how COTA's real-world data platform can benefit payers.

Transcript

COTA has announced that it will partner with Horizon Blue Cross Blue Shield of New Jersey. How can payers benefit from COTA’s real-world data platform?

I think it’s very important to understand that payers' current view of a patient’s medical treatment and cancer journey is through claims data, and for anyone familiar with claims data, it is often fragmented, incomplete, and can often times be not very accurate. COTA’s platform on the other hand, by exposing and bringing forth real-world data, can help lend a clear granular view into that patient’s treatment journey. We capture many treatment variables, including performance status, the cancer diagnosis, the cancer’s actual pathology make up, the treatment regimen, the drugs used, the toxicities, as well as the patient’s journey through their treatment history.

What COTA does is we then take that real-world data and we assign a specific code to the patient, called the CNA [Cota Nodal Address]. What the CNA essentially serves as is it allows a provider or allows any entity to view patients by their groupings, and patients with identical CNAs are technically clinically similar patients that should have been treated very similarly, and hopefully have very similar outcomes. With the use of CNA in conjunction with claims data, all of a sudden, payers are now given a clear view into what truly happens to a patient .What we’re finding is payers can then use this information, or the healthcare system can use this information to help payers understand the multiple variables that take place in a patient’s treatment, and in the current day of the ever increasing cost of cancer care, I think we’re seeing that payers are very excited to use the CNA and to use also real-world data in an attempt to work with providers to help control costs.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up